Details on the work leading to the discovery of the second-generation SARS-CoV-2 main protease (Mpro) inhibitor PF-7817883 (ibuzatrelvir) were disclosed recently by Pfizer Inc. The drug is in phase II clinical development for the treatment of adult individuals with COVID-19 symptoms who are not hospitalized.
Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of RNA polymerase II (RNAPII).
Functionally active hepatitis B virus (HBV) DNA is open and accessible, while the action of an epigenetic editor turns it into functionally inactive DNA, which is closed and inaccessible. Chroma Medicine Inc. has presented data regarding their epigenetic editor CRMA-1001, which is delivered by lipid nanoparticles.
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
The management of obesity and its associated comorbidities needs novel approaches for safety and efficacy. Researchers from Pep2tango Therapeutics Inc. are aiming to face this challenge by developing an approach that promotes superior weight loss through the loss of fat mass only, while preserving the muscle lean mass.
How do exercise and insulin collaborate in metabolism? The European Association for the Study of Diabetes (EASD) and the Novo Nordisk Foundation recognized the work of Juleen Zierath in this topic with the Diabetes Prize for Excellence at their recent annual meeting.
Secondary progressive multiple sclerosis (SPMS) is a chronic form of disease that occurs after relapsing-remitting MS, with a progressive disease course, and its pathogenesis remains unclear. CX3C chemokine receptor 1 (CX3CR1) is a G protein-coupled receptor that may be a useful marker of Eomes+ Th cells; the antigen has been shown to be expressed by cytotoxic Th cells and required for late-onset disease.
Previous research has demonstrated that patients treated with the second-generation antipsychotic olanzapine (OLA) have metabolic dysfunctions and insulin resistance. Researchers from Instituto de Investigaciones Biomedicas “Alberto Sols” and collaborators investigated the impact of intraperitoneal (i.p.) OLA treatment on peripheral insulin sensitivity as well as potential effects of inhibiting the protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling.
RSS
